Revised Prices of Anti-Cancer Medicines Come Into Effect, Offering Relief to Patients

India : Revised prices of several anti-cancer medicines came into effect across the country on Monday, marking a significant step towards reducing the financial burden on patients undergoing cancer treatment. The initiative, implemented by the National Pharmaceutical Pricing Authority (NPPA), is expected to generate annual savings of approximately Rs 3,502.31 crore for consumers.

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, announced the revised pricing structure following the decision to rationalise trade margins on 137 identified non-scheduled anti-cancer medicines. The measure aims to prevent excessive markups in the pharmaceutical distribution chain and improve the affordability of essential medicines.

According to the government, 76 pharmaceutical companies had submitted revised maximum retail prices (MRPs) for 1,225 anti-cancer formulations covering 121 drugs. Of these, 1,031 formulations recorded price reductions, while around 600 brands reported cuts exceeding 50 per cent. The highest reduction reported was 96.45 per cent.

The revised prices are based on the trade margin rationalisation order issued by the NPPA on October 17, 2026, under the provisions of the Drugs (Prices Control) Order, 2013. The authority has fixed a maximum permissible trade margin of 30 per cent on the identified medicines to address substantial differences between manufacturing and retail prices.

Cancer treatment frequently involves multiple stages of medical intervention, including diagnostic investigations, surgery, chemotherapy, radiation therapy, immunotherapy and long-term medication. For many patients, the cost of medicines represents a considerable portion of their overall treatment expenditure, particularly when specialised drugs are required over extended periods.

The latest intervention is intended to make several commonly prescribed cancer medicines more accessible by reducing the amount patients pay at pharmacies and hospitals.

Among the formulations covered by the revised pricing framework are medicines containing Bevacizumab, Denosumab, Abiraterone acetate, Pegfilgrastim, Azacitidine, Enzalutamide, Fulvestrant, Palbociclib, Pemetrexed and Pertuzumab. These medicines are used in the management of different cancers, including breast, prostate, lung, ovarian, cervical and blood cancers.

The revised prices show substantial differences across several brands. For instance, the MRP of Bryxta, a Bevacizumab 100 mg injection manufactured by Zydus Lifesciences, has been reduced from Rs 25,995 to Rs 3,318. Similarly, the price of ReliTrexed, a Pemetrexed 500 mg vial, has come down from Rs 9,977 to Rs 1,113.

Another major reduction has been reported in the case of Palbopro, a Palbociclib 125 mg capsule, whose price has fallen from Rs 40,421.33 to Rs 2,720. Such medicines are used in specialised cancer treatment and can involve substantial expenses for households.

The government said the revised pricing arrangement would also apply to identified medicines that have not yet been introduced in the Indian market. Approximately 10 to 15 drugs among the 137 identified formulations are yet to be launched domestically, but manufacturers will have to follow the prescribed trade margin provisions when they become available.

The pricing exercise is based on recommendations made by an expert committee constituted by the Directorate General of Health Services under the Union Health Ministry. The committee examined the issue of excessive trade margins and the need to improve access to essential anti-cancer medicines.

The government has maintained that rationalising distribution margins would help ensure that patients are not required to pay disproportionately high prices for medicines. The policy also seeks to balance affordability with the need to maintain legitimate returns for pharmaceutical manufacturers.

Under the revised requirements, manufacturers must communicate the updated prices to the NPPA and ensure that the revised MRPs are circulated among distributors, retailers, hospitals and other medical institutions. Pharmacies and healthcare establishments have also been directed to display the updated price lists prominently on their premises and websites.

Hospitals and medical institutions have a particularly important role in implementing the changes because a substantial quantity of anti-cancer medicines is supplied directly to them. The government has instructed these institutions to ensure that patients are charged according to the revised prices from the date of implementation.

State Drug Controllers will monitor compliance among manufacturers, dealers, pharmacies and hospitals. Regulatory authorities can take appropriate action if establishments continue charging amounts above the permitted prices or fail to implement the revised pricing requirements.

Consumers can verify the updated MRPs through the NPPA’s official website and the Pharma Sahi Daam mobile application. The government has also provided a dedicated helpline, 1800-11-1255, for complaints relating to violations of medicine pricing regulations. Complaints can additionally be submitted through the authority’s designated monitoring email address.

The initiative is significant for families dealing with prolonged cancer treatment, where repeated purchases of specialised medicines can place considerable pressure on household finances. Patients requiring targeted therapies and other advanced treatment options may particularly benefit from lower medicine prices.

Cancer care often requires a coordinated approach involving oncologists, surgeons, radiologists, pathologists, pharmacists and other healthcare professionals. Alongside medical services, access to affordable medicines remains essential for ensuring continuity of treatment.

Financial difficulties can sometimes force families to postpone treatment, reduce expenditure on other necessities or struggle to maintain prescribed medication schedules. Lower prices may help reduce some of these pressures, although the overall cost of cancer care will continue to depend on the type of disease, its stage, treatment requirements and hospital facilities.

The government has also emphasised the importance of maintaining adequate production and supply of the affected formulations. Price reductions are expected to be implemented without disrupting the availability of medicines in the market.

Pharmaceutical companies will remain responsible for complying with the revised pricing provisions while maintaining regular supplies. This requirement is important because patients undergoing cancer treatment often depend on uninterrupted access to specific medicines.

The revised pricing framework represents a broader effort to strengthen affordability within India’s healthcare system. While public health programmes and insurance coverage can provide financial assistance, medicine prices remain an important factor in determining how easily patients can access specialised treatment.

The government expects the latest intervention to benefit patients across different income groups and improve access to essential cancer medicines. Continued monitoring by regulatory authorities will be necessary to ensure that the intended reductions reach consumers and are reflected in actual retail and hospital bills.

The NPPA’s revised pricing lists are being updated as companies submit their latest information. Patients and caregivers have therefore been advised to check the applicable MRP of their prescribed formulations rather than relying on older price lists.

With the new rates taking effect from November 9, the government has placed responsibility on the entire pharmaceutical supply chain to ensure transparent pricing and compliance with the revised provisions.